Form 4: Elanco Director Receives Annual Equity Award

Elanco Animal Health Inc. director Kapila K. Anand was granted 10,314 deferred stock units as part of an annual equity award.

Summary

• Kapila K. Anand, a director at Elanco Animal Health Inc. (ELAN), received an annual equity award.
• The award consisted of 10,314 deferred stock units of common stock.
• The transaction occurred on November 28, 2025, with a reported price of $0, indicating a grant rather than a purchase.
• Following this transaction, Anand Kapila K. beneficially owns 94,973 shares of Elanco common stock directly.
• This grant is part of the annual equity awards for non-employee members of the Board of Directors.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. It's a routine compensation event, indicating stable corporate governance and aligning director interests with shareholders, but doesn't reflect operational performance.

Positives

• The grant of deferred stock units aligns the director's interests with long-term shareholder value.
• It represents a standard practice for compensating non-employee directors, indicating stable corporate governance.

Risks

• Minor potential for dilution for existing shareholders from the issuance of new shares for the award.
• Potential for future stock sales by the director upon vesting, which could exert downward pressure on the stock price.

Future Outlook

NA

Industry Context

This routine equity grant to a non-employee director is a standard compensation practice across many industries, including the animal health sector, aimed at aligning director incentives with long-term company performance.

Comparison to Industry Standards

• The grant of deferred stock units as an annual equity award to non-employee directors is a common compensation practice in publicly traded companies, including those in the pharmaceutical and animal health sectors.
• Companies like Zoetis Inc. (ZTS) and IDEXX Laboratories, Inc. (IDXX) also utilize similar equity-based compensation structures to incentivize their board members and align their interests with shareholders.
• The specific number of units granted would typically be benchmarked against peer companies based on factors like company size, director responsibilities, and overall compensation philosophy.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution from the issuance of new shares (or use of treasury shares) for the award; improved alignment of director interests with long-term shareholder value.
• Management/Directors: Standard compensation for services, incentivizing long-term commitment.

Key Dates

Recommendation

This Form 4 filing details a routine annual equity award to a non-employee director, which is a standard compensation practice. It does not provide new operational or financial performance data that would warrant a change in investment recommendation. The transaction itself is neutral, aligning director interests with shareholders but not indicating any significant shift in the company's fundamentals or outlook.

Keywords

Elanco Animal Health, ELAN, Form 4, Insider Transaction, Equity Award, Deferred Stock Units, Director Compensation, Stock Grant